Influence of N-butylscopolamine on SUV in FDG PET of the bowel

Annals of Nuclear Medicine

Volumn 23, Issue 5, 2009, Pages 471-478

  Sanghera, Bal ^a   Emmott, Jennifer ^a   Wellsted, David ^b   Chambers, Jane ^a   Wong, Wai Lup ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Artefact; Buscopan; Correction; Correlation; PET CT; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; CANCER PATIENT; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; ANTIDIARRHEALS; BLOOD GLUCOSE; BODY WEIGHTS AND MEASURES; BUTYLSCOPOLAMMONIUM BROMIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INTESTINES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 70349563436     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0263-3     Document Type: Article

References (20)

1. N Pandit-Taskar H Schöder M Gonen SM Larson HW Yeung 2004 Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET Am J Roentgenol 183 1143 1147
2. H Prabhakar D Sahani A Fischman PR Mueller MA Blake 2007 Bowel hot spots at PET-CT Radiographics 27 145 159 17235004 10.1148/rg.271065080
3. A Stahl WA Weber N Avril M Schwaiger 2000 Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen Nuklearmedizin 39 241 245 11189901 1:CAS:528:DC%2BD3MXjtV2jug%3D%3D
4. J Emmott B Sanghera J Chambers WL Wong 2008 The effects of N-butylscopolamine on bowel uptake: an 18F-FDG PET study Nucl Med Commun 29 11 16 18049092 10.1097/MNM.0b013e3282f1d706 (Pubitemid 351339335)
5. LK Shankar JM Hoffman S Bacharach MM Graham J Karp AA Lammertsma, et al. 2006 Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials J Nucl Med 47 1059 1066 16741317 1:CAS:528:DC%2BD28XmtlWmt7s%3D
6. HW Yeung A Sanches OD Squire HA Macapinlac SM Larson YE Erdi 2002 Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter Eur J Nucl Med Mol Imaging 29 61 66 11807608 10.1007/s00259-001-0662-8 1:CAS:528:DC%2BD38XitFamsQ%3D%3D (Pubitemid 34143430)
7. KR Zasadny RL Wahl 1993 SUV of normal tissues at PET 18-F FDG: variations with body weight and a method for correction Radiology 189 847 850 8234714 1:STN:280:DyaK2c%2Flt1Kiug%3D%3D
8. N Paquet A Albert J Foidart R Hustinx 2004 Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues J Nucl Med 45 784 788 15136627 1:CAS:528:DC%2BD2cXnsFygt7k%3D
9. CK Kim NC Gupta 1996 Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction Nucl Med Commun 17 890 894 8951911 1:STN:280:DyaK2s7gvFKgsw%3D%3D
10. Y Sugawara R Zasadnyk AW Neuhoff RL Wahl 1999 Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction Radiology 213 521 525 10551235 1:STN:280:DC%2BD3c%2FhvV2gsA%3D%3D
11. WA Hallett PK Marsden BF Cronin MJ O'Doherty 2001 Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer Eur J Nucl Med 28 919 922 11504091 10.1007/s002590100561 1:CAS:528:DC%2BD3MXkvVWltbo%3D (Pubitemid 32662557)
12. CO Wong J Thie KJ Parling-Lynch D Zakalik JH Margolis M Gaskill, et al. 2005 Glucose-normalized standardized uptake value from 18F-FDG PET in classifying lymphomas J Nucl Med 46 1659 1663 16204716
13. M Hadi SL Bacharach M Whatley SK Libutti SE Straus VK Rao, et al. 2008 Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV Nucl Med Biol 35 441 445 18482681 10.1016/j.nucmedbio.2008.02.007 1:CAS:528: DC%2BD1cXlvF2qt7Y%3D (Pubitemid 351636477)
14. JW Keyes Jr 1995 SUV: standard uptake or silly useless value? J Nucl Med 36 1836 1839 7562051
15. J Thie 2004 Understanding the standardized uptake value, its methods, and implications for usage J Nucl Med 45 1431 1434 15347707
16. A Stahl K Ott M Schwaiger WA Weber 2004 Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET Eur J Nucl Med Mol Imaging 31 1471 1479 15257418 10.1007/s00259-004-1626-6 1:STN:280: DC%2BD2crksV2ksg%3D%3D (Pubitemid 39592766)
17. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1995 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur J Cancer 35 1773 1782 10.1016/S0959-8049(99)00229-4
18. L Richard 2004 Wahl: Why Nearly All PET of Abdominal and Pelvic Cancers Will Be Performed as PET/CT J Nucl Med 45 Suppl 1 82S 95S
19. PD Shreeve YA Anzai RL Wahl 1999 Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants Radiograhics 19 61 77
20. P Veit C Kuhle T Beyer H Kuehl CU Herborn G Borsch, et al. 2006 Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer Gut 55 68 73 15970580 10.1136/gut.2005. 064170 1:STN:280:DC%2BD2Mnmt1SrtA%3D%3D (Pubitemid 41820638)